TrialCancer medicine2024

Chidamide plus envafolimab as subsequent treatment in advanced non-small cell lung cancer patients resistant to anti-PD-1 therapy: A multicohort, open-label, phase II trial with biomarker analysis.

Yaxiong Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.